====== Pilocytic astrocytoma ====== ===== Latest news ===== {{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1tUjNYI-_9Jy-9DO1hLvAx0YCDCdQTFJ3ScwWe4M7F9mrGggWn/?limit=15&utm_campaign=pubmed-2&fc=20221213065304}} ===== Key concepts ===== ● a subgroup of [[astrocytoma]]s ([[WHO grade I]]) with better [[prognosis]] (10-year survival: > 95%) than infiltrating [[fibrillary astrocytoma]] or [[diffuse astrocytoma]]s ● the most common [[astrocytic tumor]] in [[child]]ren ● the average age is lower than for typical [[astrocytoma]]s (75% of patients are ≤ 20 yrs) ● common locations: [[cerebellar hemisphere]], [[optic nerve]]/[[chiasm]], [[hypothalamus]] ● CT/MRI appearance: discrete appearing, contrast-enhancing lesion. [[Cerebellar pilocytic astrocytoma]]s are classically cystic with a mural nodule ● the principal CNS tumor associated with [[NF1]] ● pathology: biphasic. 1) Compacted, 2) loose textured astrocytes with Rosenthal fibers and/or eosinophilic granular bodies ● the danger of over grading and overtreating if not recognized. Histology alone may be inadequate for diagnosis; knowledge of patient age & radiographic appearance is critical ● complete surgical resection, when possible, is usually curative. For cystic PCAs with enhancing mural nodule, only the [[nodule]] needs to be resected (the cyst wall is not neoplastic). [[XRT]] is used post-op only for nonresectable recurrence or malignant degeneration. ===== Background and terminology ===== Pilocytic astrocytoma is typically grouped under the circumscribed astrocytic [[glioma]] in the [[World Health Organization Classification of Tumors of the Central Nervous System 2021]]. The distinction of [[pilocytic astrocytoma]] from [[diffuse glioma]] is fundamental as it could be the difference between CNS WHO grade 1 and grade 4 glioma ((Alturkustani M. Infiltration in Pilocytic Astrocytoma: A Diagnostic Pitfall. Cureus. 2022 Aug 12;14(8):e27940. doi: 10.7759/cureus.27940. PMID: 36120224; PMCID: PMC9464476.)). ---- Pilocytic [[astrocytoma]] (PCA) is the currently recommended nomenclature for these tumors previously referred to variously as [[cystic cerebellar astrocytoma]]s and [[juvenile pilocytic astrocytoma]]s (JPA), among others. Based on location, subtypes include [[optic glioma]]s, [[hypothalamic glioma]]s, and [[cerebellar pilocytic astrocytoma]]s. Since treatment decisions vary based on location and neural involvement, it is helpful to discuss differences in the [[management]] of these subtypes. PCAs differ markedly from infiltrating [[fibrillary astrocytoma]]s in terms of their reduced tendency to invade tissue and their very low propensity for malignant degeneration. ===== Epidemiology ===== [[Pilocytic astrocytoma epidemiology]]. ===== Etiology ===== It is driven by aberrant mitogen-activated protein kinase signaling most commonly caused by BRAF gene fusions or activating mutations It is most frequently caused by KIAA1549:BRAF fusions and leads to oncogene-induced senescence (OIS). OIS is thought to be a major reason for the growth arrest of PA cells in vitro and in vivo, preventing the establishment of PA cultures ((Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Marquardt V, Pauck D, Bächli H, Stiles CD, von Deimling A, Remke M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, Milde T. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget. 2016 Dec 17. doi: 10.18632/oncotarget.14004. [Epub ahead of print] PubMed PMID: 28002790. )). ====Molecular heterogeneity==== For tumors originating in the supra-or infratentorial location, a different molecular background was suggested, but plausible correlations between the transcriptional profile and radiological features and/or clinical course are still undefined. It is a clinically and molecularly heterogeneous disease that occurs most often in the cerebellum and hypothalamic and chiasmatic regions. Classically, pilocytic astrocytomas are driven by the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Genetic aberrations involving this pathway are critical for tumorigenesis. Tandem duplication of 7q34 encodes BRAF and produces several KIAA1549-BRAF novel oncogenic fusions. Activating point mutations of BRAF, such as BRAF (V600E), also lead to pilocytic astrocytoma. Loss of the NF1 gene allows hyperactivation of the oncogene KRAS. A better understanding of the evolving molecular heterogeneity of pilocytic astrocytomas offers hope for developing molecularly targeted therapeutic armamentariums ((Sadighi Z, Slopis J. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity. J Child Neurol. 2013 May;28(5):625-32. doi: 10.1177/0883073813476141. Epub 2013 Feb 25. Review. PubMed PMID: 23439714.)). Pilocytic astrocytomas of different locations can be precisely differentiated on the basis of their gene expression level, but their transcriptional profiles does not strongly reflect the radiological appearance of the tumor or the course of the disease ((Zakrzewski K, Jarząb M, Pfeifer A, Oczko-Wojciechowska M, Jarząb B, Liberski PP, Zakrzewska M. Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features. BMC Cancer. 2015 Oct 24;15:778. doi: 10.1186/s12885-015-1810-z. PubMed PMID: 26497896; PubMed Central PMCID: PMC4619381.)). ===== Classification ===== see [[Infratentorial pilocytic astrocytoma]]. ---- Pilocytic astrocytomas in the supratentorial compartment make up 20 % of all brain tumours in children with only 5 % of these arising in the suprasellar region. Suprasellar pilocytic astrocytomas are challenging to manage surgically with high morbidity rates from surgical resection. ---- Recent studies suggest that the behavior and biology of WHO grade I pilocytic astrocytomas (PAs) in adults is different than that associated with grade I PAs in children. see [[Anaplastic pilocytic astrocytoma]]. ===== Clinical features ===== The presentation depends on the location. In the [[posterior fossa tumor]]s, there is predominantly a mass effect with signs of [[raised intracranial pressure]], especially when [[hydrocephalus]] is present. Bulbar symptoms or cerebellar symptoms may also be present. see [[Cerebellar pilocytic astrocytoma]]. ===== Diagnosis ===== [[Pilocytic Astrocytoma Diagnosis]]. ===== Pilocytic Astrocytoma Differential Diagnosis ===== [[Pilocytic Astrocytoma Differential Diagnosis]]. ===== Treatment ===== [[Pilocytic astrocytoma treatment]]. ===== Outcome ===== [[Pilocytic astrocytoma]] is a benign [[low grade]] tumor with a favorable [[prognosis]]. It is mostly excellent if [[gross total resection]] can be achieved, with 10-year survival rates of up to 95%. see [[Pilocytic astrocytoma recurrence]]. ===== Case series ===== [[Pilocytic astrocytoma case series]]. ===== Case reports ===== A previously healthy 10-year-old girl presented with a loss of [[consciousness]] following a sudden [[headache]] and [[vomiting]]. A non-contrast brain [[computed tomography]] (CT) scan revealed a massive [[cerebellar hemorrhage]] with [[obstructive hydrocephalus]]; however, subsequent [[CT angiography]] ([[CTA]]) showed no vascular abnormalities. An emergency craniotomy was performed to evacuate the hematoma, and histological analysis of the specimen obtained from the tissue surrounding the hematoma revealed a [[pilocytic astrocytoma]] (PA). Six months after the ictus, her recovery was scored at 2 on the modified Rankin Scale. PA can be a cause of critical cerebellar hemorrhage. In this case of a life-threatening massive hematoma, CTA was useful to exclude a major vascular pathology and to save time ((Teshigawara A, Kimura T, Ichi S. Critical cerebellar hemorrhage due to pilocytic astrocytoma in a child: A case report. Surg Neurol Int. 2021 Sep 6;12:448. doi: 10.25259/SNI_430_2020. PMID: 34621563; PMCID: PMC8492438.)). ===== References =====